BMRN:NASDAQ
Biomarin Pharmaceutical Inc
54,69 US$
arrow_downward
-0,92%(-0,51) 1D
8 ოქტ, 14:47:49 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
54,95 US$
High
54,95 US$
Low
53,90 US$
Mkt. cap
10,59 მლრდ.
Avg. vol.
2,03 მლნ.
Volume
910,82 ათ.
P/E ratio
147,44
52-wk high
70,98 US$
52-wk low
49,26 US$
EPS
0,37 US$
Beta
0,22
Shares outstanding
193,57 მლნ.
No. of employees
3 ათ.
Open
54,95 US$
High
54,95 US$
Low
53,90 US$
Mkt. cap
10,59 მლრდ.
Avg. vol.
2,03 მლნ.
Volume
910,82 ათ.
P/E ratio
147,44
52-wk high
70,98 US$
52-wk low
49,26 US$
EPS
0,37 US$
Beta
0,22
Shares outstanding
193,57 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Yahoo Finance
·
33 წუთის წინ
BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?
Simply Wall Street
·
2 საათის წინ
Is BioMarin Pharmaceutical (BMRN) Below Fair Value After New Clinical Data And Its AI Deal?
Zacks
·
1 დღის წინ
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
AD HOC NEWS
·
1 დღის წინ
BioMarin flags USD 283 million charge. BioMarin stock loses 1.83 percent.
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOალექსანდერ ჰარდი
Employees3,22 ათ.
Foundedმარ 1997
HeadquartersSan Rafael, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitebiomarin.com